View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferenc...

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences CORAL GABLES, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming investor conferences detailed below. Piper Sandler 36th...

 PRESS RELEASE

Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to...

Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work CORAL GABLES, Fla., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it has been named on the BioSpace 2025 Best Places to Work. Catalyst is among 50 U.S. operating employers on the Best Places to Work list. The recipients are recognized as the most sought-af...

 PRESS RELEASE

Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial R...

Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update Reports Q3 2024 Total Revenues of $128.7 Million, Representing a 25.3% YoY Increase Record Revenues Driven by Continued Organic Growth in its Rare Disease Franchise Robust Financial Performance Highlights Operational Excellence and Strong Commercial Execution FIRDAPSE® Q3 2024 Net Product Revenues of $79.3 Million, Representing a 19.7% YoY Increase AGAMREE® Q3 2024 Net Product Revenues of $15.0 Million, Demonstrating Early U.S. Launch Success FYCOMPA® Q3 2024 Net Product Revenues...

 PRESS RELEASE

IRADIMED CORPORATION Named to Fortune’s 100 Fastest Growing Companies ...

IRADIMED CORPORATION Named to Fortune’s 100 Fastest Growing Companies List for 2024 WINTER SPRINGS, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) was recently named one of Fortune’s 100 Fastest Growing Companies for 2024. Iradimed is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures. “Being recognized by Fortune as o...

 PRESS RELEASE

IRADIMED CORPORATION Announces Third Quarter of 2024 Financial Results...

IRADIMED CORPORATION Announces Third Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share Reports record revenue of $18.3 million for the third quarter of 2024, an increase of $1.8 million or 11% over the comparable period 2023.Reports GAAP diluted EPS of $0.40 and Non-GAAP diluted EPS of $0.43 for the third quarter of 2024.Raising year end guidance on GAAP diluted earnings per share to $1.49 to $1.52 from $1.37 to $1.47, and Non-GAAP diluted earnings per share to $1.64 to $1.67 from $1.52 to $1.62. Declares a regular quarterly cash...

 PRESS RELEASE

Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Result...

Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024 The Company will Host a Conference Call and Webcast on Thursday, November 7, 2024, at 8:30 AM ET CORAL GABLES, Fla., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its third quarter 2024 financial results after the market c...

 PRESS RELEASE

Yext Expands AI Review Generation to Include Third-Party Sites

NEW YORK--(BUSINESS WIRE)-- (NYSE: YEXT), the leading digital presence platform for multi-location brands, today announced the launch of its expanded AI Review Generation solution. This powerful tool enables enterprises to request and manage reviews across more than 80 supported review sites, including Google and Facebook, alongside their own channels. The AI Review Generation feature streamlines the collection, management, and response workflows within a single platform, simplifying the process of building and safeguarding online reputations. Recent reveals that 71% of customers consider r...

 PRESS RELEASE

Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hu...

Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts CORAL GABLES, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "the Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel therapies for patients with rare diseases, today announced that it has contributed $100,000 to the American Red Cross to support ongoing relief efforts for communities impacted by Hurricane Helene. "At Catalyst, our commitment to the community is unwave...

 PRESS RELEASE

IRADIMED CORPORATION to Participate in the 3rd Annual ROTH Healthcare ...

IRADIMED CORPORATION to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference WINTER SPRINGS, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today that it will participate in the 3rd Annual ROTH Healthcare Opportunities Conference.  Iradimed’s CFO, Jack Glenn, will host one-on-one meetings with investors at the 3rd Annual ROTH Healthcare Opportunities Conference at the Metropolitan Club in New York on October 9, 2024. About I...

 PRESS RELEASE

Catalyst Pharmaceuticals to Participate in the BofA Securities CNS The...

Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024 CORAL GABLES, Fla., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming BofA Securities CNS Therap...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received A...

Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE® in Japan CORAL GABLES, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that its sub-licensee in Japan, DyDo Pharma, Inc., ("DyDo") has reported that the Ministry of Health, Labor and Welfare of Japan has approved DyDo's New Drug Application ("NDA") t...

Yext Inc: 1 director

A director at Yext Inc bought 32,600 shares at 6.646USD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...

 PRESS RELEASE

IRADIMED CORPORATION To Participate in the Lake St. Annual Best Ideas ...

IRADIMED CORPORATION To Participate in the Lake St. Annual Best Ideas Growth “Big 8” Investor Conference WINTER SPRINGS, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today that the Company will be participating in the Lake Street 8th Annual Best Ideas Growth "Big 8" Conference. Iradimed management will host one-on-one meetings between company management and investors at the Lake Street 8th Annual Best Ideas Growth "Big 8" Conference at the ...

 PRESS RELEASE

Introducing Yext Social: A New AI-Powered Standard in Local Social Eng...

NEW YORK--(BUSINESS WIRE)-- (NYSE: YEXT), the leading digital presence platform for multi-location brands, today announced the launch of Yext Social, a cutting-edge AI-powered social media management solution that transforms how brands manage local customer engagement at scale globally. Yext Social empowers brands to connect with customers where it matters most—locally—through personalized, data-driven content, all managed on a single platform. Yext Social represents a major expansion of the Yext platform. Leveraging advanced AI technology, Yext Social simplifies content creation, optimizes ...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Yext Announces Second Quarter Fiscal 2025 Results

NEW YORK--(BUSINESS WIRE)-- Yext, Inc. (NYSE: YEXT), the leading digital presence platform for multi-location brands, today announced its results for the three months ended July 31, 2024, or the Company's second quarter of fiscal year 2025. For more detailed information on the Company's operating and financial results for the second quarter fiscal 2025, as well as the Company's outlook for its third quarter and fiscal year 2025, please reference the Letter to Shareholders on its Investor Relations website at . "Our second quarter results delivered significant margin expansion due to our co...

Catalyst Pharmaceuticals Inc: 1 director

A director at Catalyst Pharmaceuticals Inc sold 150,000 shares at 20.353USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...

 PRESS RELEASE

Yext to Announce Second Quarter Fiscal Year 2025 Financial Results on ...

NEW YORK--(BUSINESS WIRE)-- Yext, Inc. (NYSE: YEXT), the leading digital presence platform for multi-location brands, today announced that its second quarter fiscal year 2025 results will be released on Wednesday, September 4, 2024, after the close of the market. The company will host a conference call at 5:00 p.m. (ET) / 2:00 p.m. (PT) to discuss its financial results with the investment community. A live webcast of the event will be available on the Yext Investor Relations website at . A live dial-in is available domestically at (877) 883-0383 and internationally at (412) 902-6506, passcod...

 PRESS RELEASE

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferenc...

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences CORAL GABLES, Fla., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming investor conferences detailed below. 2024 Wells Fargo H...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch